</s><s><s><s> human papillomavirus ( hpv ) 16/18-as04-adjuvanted vaccines have been approved by the us food and drug administration ( fda ) and the us department of health and human services ( hhs ) for the prevention and treatment of disease associated with hpv in the united states, europe, and africa. 
 these adjuvanted vaccines are currently available for the treatment of hpv - related disease in the us and europe. in this article 
, we review the literature on the safety and efficacy of these vaccines, the economic and health care implications of their use, and the cost-effectiveness of a potential vaccine for hpv. </s>